Cybin Inc. (OTCMKTS:CLXPF) Receives Average Rating of “Buy” from Analysts

Cybin Inc. (OTCMKTS:CLXPF) has earned an average recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $10.50.

Several equities research analysts have recently weighed in on the company. Stifel Nicolaus increased their price target on Cybin from C$11.00 to C$15.00 and gave the stock a “buy” rating in a report on Monday, June 21st. They noted that the move was a valuation call. HC Wainwright assumed coverage on Cybin in a report on Monday, July 26th. They issued a “buy” rating and a $8.00 price target on the stock. Aegis started coverage on Cybin in a report on Thursday, July 8th. They issued a “buy” rating and a $9.00 price target on the stock. Finally, Zacks Investment Research downgraded Cybin from a “buy” rating to a “hold” rating in a report on Tuesday, August 3rd.

Shares of OTCMKTS CLXPF traded down $0.05 during midday trading on Friday, hitting $2.03. The company’s stock had a trading volume of 1,098,097 shares, compared to its average volume of 551,962. The business’s 50 day moving average is $2.29 and its two-hundred day moving average is $2.00. Cybin has a 12-month low of $0.49 and a 12-month high of $3.38. The firm has a market cap of $301.65 million and a P/E ratio of -8.46.

About Cybin

Cybin Inc, a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products.

See Also: Investing strategies using the yield curve

Analyst Recommendations for Cybin (OTCMKTS:CLXPF)

Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with's FREE daily email newsletter.